[1]查小云,魏长顺,吴金枝,等.新诊断2型糖尿病患者血C肽水平与10年内动脉粥样硬化性心血管疾病发生风险的相关性分析[J].福建医药杂志,2024,46(08):17-21.[doi:10.20148/j.fmj.2024.08.005]
　ZHA Xiaoyun,WEI Changshun,WU Jinzhi,et al.Association between C-peptide level and 10-year risk of ASCVD in patients with newly diagnosed type 2 diabetes mellitus[J].FUJIAN MEDICAL JOURNAL,2024,46(08):17-21.[doi:10.20148/j.fmj.2024.08.005]
点击复制

新诊断2型糖尿病患者血C肽水平与10年内动脉粥样硬化性心血管疾病发生风险的相关性分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年08期
页码:
17-21
栏目:
临床研究
出版日期:
2024-12-20

文章信息/Info

Title:
Association between C-peptide level and 10-year risk of ASCVD in patients with newly diagnosed type 2 diabetes mellitus
文章编号:
1002-2600(2024)08-0017-05
作者:
查小云; 魏长顺; 吴金枝; 谢良孝; 赖鹏斌
福建医科大学附属漳州市医院内分泌代谢一科,漳州 363000
Author(s):
ZHA Xiaoyun; WEI Changshun; WU Jinzhi; XIE Liangxiao; LAI Pengbin
The First Department of Endocrinology and Metabolism, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, Fujian 363000, China
关键词:
2型糖尿病;  空腹C肽;  ASCVD风险
Keywords:
type 2 diabetes;  fasting C-peptide;  risk of ASCVD
分类号:
R589.1
DOI:
10.20148/j.fmj.2024.08.005
文献标志码:
B
摘要:
目的 分析新诊断2型糖尿病(T2DM)患者血清C肽水平对10年内发生动脉粥样硬化性心血管疾病(ASCVD)的风险的影响。方法 选取新诊断T2DM患者345例,根据空腹C肽(FCP)水平四分位数将患者分为4组,应用China-PAR模型评估10年内发生ASCVD的风险。结果 高FCP水平(>0.980 ng/mL)与较高的10年ASCVD风险相关,且这种关系受性别和体重影响。多元线性回归分析显示,校正性别、年龄、BMI、糖化血红蛋白等混杂因素后,FCP仍然能正向预测10年ASCVD风险。结论 高FCP水平是新诊断T2DM患者未来ASCVD风险的一个危险因素。
Abstract:
Objective To analyze the impact of serum C-peptide levels in patients with newly diagnosed type 2 diabetes(T2DM)on the 10-year risk of atherosclerotic cardiovascular disease(ASCVD).Methods A total of 345 patients with newly diagnosed T2DM were selected and categorized into four groups based on fasting C-peptide(FCP)level quartiles.The China-PAR model was employed to evaluate the 10-year ASCVD risk.Results Elevated FCP levels(greater than 0.980 ng/ml)were found to be associated with an increased 10-year ASCVD risk with this relationship being moderated by gender and weight.Multiple linear regression analysis indicated that, after adjusting confounding factors such as gender, age, BMI, and glycosylated hemoglobin, FCP levels remained a positive predictor of 10-year ASCVD risk.Conclusion High FCP levels constitute a significant risk factor for future ASCVD in patients with newly diagnosed T2DM.

参考文献/References:

[1] JIA W, WENG J, ZHU D, et al.Standards of medical care for type 2 diabetes in China 2019[J].Diabetes Metab Res Rev, 2019, 35(6): e3158.
[2] VIIGIMAA M, SACHINIDIS A, TOUMPOURLEKA M, et al.Macrovascular complications of type 2 diabetes mellitus[J].Curr Vasc Pharmacol, 2020, 18(2): 110-116.
[3] ARNETT D K, BLUMENTHAL R S, ALBERT M A, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Circulation, 2019, 140(11): e563-e595.
[4] STANDL E, JANKA H U.High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes[J].Horm Metab Res Suppl, 1985, 15: 46-51.
[5] GEDEBJERG A, BJERRE M, KJAERGAARD A D, et al.CRP, C-Peptide, and risk of first-time cardiovascular events and mortality in early type 2 diabetes: A Danish cohort study[J].Diabetes Care, 2023, 46(5): 1037-1045.
[6] JAHROMI M K, AHMADIRAD H, JAMSHIDI S, et al.The association of serum C-peptide with the risk of cardiovascular events: a meta-analysis and systematic review[J].Diabetol Metab Syndr, 2023, 15(1): 168.
[7] WAHAB M A, ALHABIBI A M, SAKR A K, et al.The correlation Between C-peptide and severity of peripheral atherosclerosis in type 2 diabetes mellitus[J].Diabetes Metab Syndr Obes, 2023, 16: 2617-2625.
[8] WANG Y, WAN H, CHEN Y, et al.Association of C-peptide with diabetic vascular complications in type 2 diabetes[J].Diabetes Metab, 2020, 46(1): 33-40.
[9] TOFFOLO G, DE GRANDI F, COBELLI C.Estimation of beta-cell sensitivity from intravenous glucose tolerance test C-peptide data.Knowledge of the kinetics avoids errors in modeling the secretion[J].Diabetes, 1995, 44(7): 845-854.
[10] TOPRAK K, KAPLANGORAY M, PALICE A.The impact of C-peptide and diabetes mellitus on coronary ectasia and effect of coronary ectasia and C-peptide on long-term outcomes: A retrospective cohort study[J].Int J Clin Pract, 2022, 2022: 7910566.
[11] QIN J, SUN R, DING D.Effects of serum C-peptide level on blood lipid and cardiovascular and cerebrovascular injury in patients with type 2 diabetes mellitus: A Meta-analysis[J].Contrast Media Mol Imaging, 2022, 2022: 6314435.
[12] YAN S T, SUN J, GU Z Y, et al.The bidirectional association of C-peptide with cardiovascular risk in nondiabetic adults and patients with newly diagnosed type 2 diabetes mellitus: a retrospective cohort study[J].Cardiovasc Diabetol, 2022, 21(1): 201.
[13] KAUTZKY-WILLER A, LEUTNER M, HARREITER J.Sex differences in type 2 diabetes[J].Diabetologia, 2023, 66(6): 986-1002.
[14] LIU J, JIN X, LIU W, et al.The risk of long-term cardiometabolic disease in women with premature or early menopause: A systematic review and meta-analysis[J].Front Cardiovasc Med, 2023, 10: 1131251.
[15] SHI S, NI L, TIAN Y, et al.Association of obesity indices with diabetic kidney disease and diabetic retinopathy in type 2 diabetes: A real-world study[J].J Diabetes Res, 2023, 2023: 3819830.
[16] AUSK K J, BOYKO E J, IOANNOU G N.Insulin resistance predicts mortality in nondiabetic individuals in the U.S[J].Diabetes Care, 2010, 33(6): 1179-1185.
[17] PATEL N, TAVEIRA T H, CHOUDHARY G, et al.Fasting serum C-peptide levels predict cardiovascular and overall death in nondiabetic adults[J].J Am Heart Assoc, 2012, 1(6): e3152.
[18] CHEN J, HUANG Y, LIU C, et al.The role of C-peptide in diabetes and its complications: an updated review[J].Front Endocrinol(Lausanne), 2023, 14: 1256093.
[19] LEE S K, LEE J O, KIM J H, et al.C-peptide stimulates nitrites generation via the calcium-JAK2/STAT1 pathway in murine macrophage Raw264.7 cells[J].Life Sci, 2010, 86(23-24): 863-868.
[20] MARX N, WALCHER D, RAICHLE C, et al.C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro[J].Arterioscler Thromb Vasc Biol, 2004, 24(3): 540-545.

相似文献/References:

[1]姚奇棋 林国新 陈金星 陈振新 李素梅.利拉鲁肽治疗超重或肥胖2型糖尿病患者的临床疗效[J].福建医药杂志,2017,39(5):98.
[2]潘金兴 姜锋.老年2型糖尿病患者血清CA199水平及其与血糖的相关性[J].福建医药杂志,2017,39(5):119.
[3]祖水玲,李海秀,黄平辉,等.改良版八段锦对2型糖尿病患者焦虑、抑郁状况的影响[J].福建医药杂志,2021,43(04):28.

备注/Memo

备注/Memo:
通信作者:赖鹏斌,Email:13709398727@163.com
更新日期/Last Update: 2024-12-20